Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,303 matching trials from the live ClinicalTrials.gov search.
Conditions
Heart Failure
Interventions
Health Guide using AHA heart failure protocols and content
Device
Lead sponsor
American Heart Association
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Warrensville Heights, Ohio
Conditions
Supraventricular Tachycardia (SVT)
Interventions
IV adenosine, IV diltiazem
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Ischemic Stroke
Interventions
Thermogard XP3, Recanalization only
Device · Procedure
Lead sponsor
ZOLL Circulation, Inc., USA
Industry
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Marietta, Georgia • Honolulu, Hawaii • Chicago, Illinois + 4 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 85 Years
Enrollment
48,262 participants
Timeline
2011 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 3 Interventional Results available

Bexagliflozin Efficacy and Safety Trial

NCT02558296
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
40 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
66
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Azusa, California + 57 more
Completed Phase 3 Interventional Results available

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

NCT01951885
Conditions
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Hodgkins Disease, Chronic Lymphocytic Leukemia, Multiple Myeloma
Interventions
tacrolimus, methotrexate, Mycophenolate mofetil, Methotrexate (low dose)
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Ischemic Stroke, Acute Stroke
Interventions
Zoom Reperfusion System
Device
Lead sponsor
Imperative Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
28
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Conditions
Venous Leg Ulcer, Venous Leg, Diabetic Foot, Diabetic Foot Ulcer, Foot Ulcer, Diabetic, Ulcer Foot, Leg Ulcer, Ulcer Venous, Ulcer
Interventions
ACApatch™, caregraFT™, Standard of Care
Other
Lead sponsor
Tiger Biosciences, LLC.
Industry
Eligibility
21 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Conditions
Diabetes Mellitus, Type 2, Coronary Restenosis
Interventions
Technetium Tc99m Sestamibi
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
21 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
7
States / cities
Hartford, Connecticut • Waterbury, Connecticut • Grand Rapids, Michigan + 4 more
Conditions
Non-proliferative Diabetic Retinopathy
Interventions
KSI-301, Sham injection
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
46
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 42 more
Conditions
Bradycardia, Tachycardia, Atrial Fibrillation, Valvular Heart Disease
Interventions
continue warfarin through the procedure, Hold warfarin, Warfarin held with heparin transition.
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Columbia, Maryland
Conditions
Systemic Lupus Erythematosus
Interventions
PET/CT, Pioglitazone, Placebo
Radiation · Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lupus Erythematosus, Systemic
Interventions
Atorvastatin, Placebo atorvastatin
Drug
Lead sponsor
Laura Schanberg
Other
Eligibility
10 Years to 21 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
Interventions
QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
Interventions
ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Phoenix, Arizona • Campbell, California • Irvine, California + 6 more
Conditions
Multiple Myeloma
Interventions
Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide, Cyclosporine, Doxorubicin hydrochloride, Etoposide, Fludarabine phosphate, Prednisone, Vincristine Sulfate, Methotrexate, GMCSF (granulocyte macrophage colony stimulating factor), GCSF (granulocyte colony stimulating factor)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Multiple Myeloma, Lymphoma, Non-Hodgkin's
Interventions
cemsidomide, Dexamethasone Oral
Drug
Lead sponsor
C4 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more
Conditions
Heart Failure, Diabetes Mellitus, Type 2
Interventions
On-screen electronic alert
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Completed Phase 2 Interventional Results available

Baricitinib in Relapsing Giant Cell Arteritis

NCT03026504
Conditions
Arteritis, Giant Cell
Interventions
Baricitinib
Drug
Lead sponsor
Matthew J Koster
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Supraventricular Tachycardia (SVT)
Interventions
adenosine, diltiazem
Drug
Lead sponsor
Anne E. Zepeski
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Atrial Fibrillation
Interventions
Microwave Ablation System
Device
Lead sponsor
Maquet Cardiovascular
Industry
Eligibility
18 Years and older
Timeline
Started 2007
U.S. locations
5
States / cities
Mesa, Arizona • Chico, California • Long Beach, California + 2 more
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Vascular Disease, Cardiovascular Diseases, PAD
Interventions
FlexStent® Femoropopliteal Self Expanding Stent System
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
35 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
36
States / cities
Phoenix, Arizona • Yuma, Arizona • Mountain View, California + 30 more
Conditions
Ischemic Stroke, Hypothermia
Interventions
Mild Hypothermia
Other
Lead sponsor
WellStar Health System
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Cardiovascular Risk Factor
Interventions
Multicomponent Virtual Lifestyle Intervention
Behavioral
Lead sponsor
Truemedicine Inc
Other
Eligibility
30 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California